Abstract
It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, companies with peak market-cap values in excess of USD 500 million to 1 billion prior to product launch regularly sell for pennies on the dollar a few years after market introduction. It is possible, however, that the market is not as broken as we perceive. That is, in the collective mind of the clinician, recently-approved antibiotics may be too-poorly differentiated to justify their broad use and inordinate cost relative to those already existing. Perhaps we in the antibacterial drug development field must change our way of thinking if we are to survive and thrive. Rather than reflexively developing new β-lactam-β-lactamase inhibitor combinations for every new enzyme that evades our current inhibitors, we should focus discovery and development efforts on agents that revolutionize how we potentiate antibiotics. To this end, there has been renewed interest in phage therapies, virulence inhibitors, bacterial growth rate modulators, monoclonal antibodies, and other approaches to augment ant...Continue Reading
References
Jan 19, 2010·Current Opinion in Microbiology·Christian Baron
Jan 1, 2009·Current Pharmaceutical Biotechnology·Jason J Gill, Paul Hyman
Sep 3, 2010·Trends in Biotechnology·Mzia Kutateladze, Revaz Adamia
Mar 4, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jenny Fernebro
Jan 17, 2012·Seminars in Cancer Biology·Casey W ShuptrineLouis M Weiner
Aug 25, 2015·Current Opinion in Microbiology·Antonio DiGiandomenico, Bret R Sellman
Nov 9, 2016·Antimicrobial Agents and Chemotherapy·Paul G AmbroseSujata M Bhavnani
Nov 30, 2016·Current Microbiology·Agata Anna CisekZbigniew Wyżewski
Jan 20, 2017·Virulence·Valéria SzijártóGábor Nagy
Jan 26, 2017·The New England Journal of Medicine·Mark H WilcoxUNKNOWN MODIFY I and MODIFY II Investigators
Nov 29, 2017·Antimicrobial Agents and Chemotherapy·Shankaramurthy ChannabasappaBharathi Sriram
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Paul G AmbroseChristopher M Rubino
Oct 22, 2018·Intensive Care Medicine·Bruno FrançoisUNKNOWN MASTER 1 study group
Nov 23, 2018·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jason P BurnhamMarin H Kollef
Nov 30, 2018·Frontiers in Pharmacology·Luca FalzoneMassimo Libra
Feb 15, 2019·Cell Host & Microbe·Kaitlyn E KortrightPaul E Turner
Feb 21, 2019·Antimicrobial Agents and Chemotherapy·Paul G AmbroseBrad Spellberg
Mar 22, 2019·Open Forum Infectious Diseases·Mariana CastanheiraRonald N Jones
Mar 27, 2019·Antimicrobial Agents and Chemotherapy·Melicent PeckJorge A Tavel
Feb 22, 2018·Pathogens & Immunity·David M Shlaes, Patricia A Bradford
May 6, 2019·The Lancet Infectious Diseases·Pierre-François LaterreBruno François
Nov 13, 2019·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraDee Shortridge
Apr 5, 2020·Antibiotics·Daniel V Zurawski, Molly K McLendon
Apr 10, 2020·The Journal of Clinical Investigation·Vance G FowlerCara Cassino
Apr 26, 2020·Antibiotics·Kathryn M StylesAntonia P Sagona
May 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Xiaoling XuHaiming Wei
May 13, 2020·Antimicrobial Agents and Chemotherapy·Razieh KebriaeiMichael J Rybak
Jun 3, 2020·European Journal of Internal Medicine·Corrado CampochiaroAlberto Zangrillo
Jul 1, 2020·Frontiers in Microbiology·Myeongjin ChoiSharon M Tennant